KALA BIO, Inc. (0JQ2.L)

6,82 -1,08 (-13,61%) Alla chiusura: 05:02PM BST

KALA BIO, Inc.

1167 Massachusetts Avenue
Arlington, MA 02476
United States
781 996 5252
https://www.kalarx.com

Settore/i: 
Settore: 
Impiegati a tempo pieno: 43

Figure dirigenziali chiave

Nome	Titolo	Retribuzione	Esercitate	Anno di nascita
Mr. Mark T. Iwicki	Chairman & CEO	1,1M	N/D	1966
Mr. Todd Bazemore	President & COO	783,04k	N/D	1970
Dr. Kim Brazzell Ph.D.	Head of R&D and Chief Medical Officer	750,91k	N/D	1953
Dr. Justin Hanes Ph.D.	Founder & Chair of the Scientific Advisory Board	N/D	N/D	N/D
Ms. Mary Reumuth CPA	CFO & Treasurer	N/D	N/D	1975
Ms. Jill S. Steier	Executive Director of Investor Relations & Corporate Communications	N/D	N/D	N/D
Mr. Eric L. Trachtenberg	Chief Legal Officer, Chief Compliance Officer & Corporate Secretary	646,56k	N/D	1973
Mr. Vincent Kosewski	Senior VP of Manufacturing & Supply Chain Management	N/D	N/D	1963
Mr. Darius Kharabi J.D., M.B.A.	Chief Business Officer	N/D	N/D	1980
Dr. Francis S. Mah M.D.	Chief Medical Advisor	N/D	N/D	N/D

Gli importi risalgono al giorno 31 dicembre 2022 e i valori di compensazione riguardano l'anno fiscale che si chiude a tale data. La retribuzione include salari, bonus ecc. "Esercitate" è il valore delle opzioni esercitate durante l'anno fiscale. Valuta in USD.

Descrizione

KALA BIO, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for the treatment of eye diseases. The company's product candidates include KPI-012, which is in Phase 2b clinical trial for the treatment of persistent corneal epithelial defects; EYSUVIS for the short-term treatment of the signs and symptoms of dry eye disease; and INVELTYS, a topical twice-a-day ocular steroid for the treatment of post-operative inflammation and pain following ocular surgery. Its preclinical development product, including KPI-014 for the treatment of rare inherited retinal diseases. The company was formerly known as Kala Pharmaceuticals, Inc. and changed its name to KALA BIO, Inc. in August 2023. KALA BIO, Inc. was incorporated in 2009 and is headquartered in Arlington, Massachusetts.

Governance aziendale

L'ISS Governance QualityScore di KALA BIO, Inc. al N/D è N/D. I criteri di valutazione fondamentali sono revisione: N/D; Consiglio di Amministrazione: N/D; diritti degli azionisti: N/D; retribuzione: N/D.

Punteggi di corporate governance forniti da Institutional Shareholder Services (ISS). I punteggi indicano il rango decile relativo all’indice o alla regione. Un punteggio di decile pari a 1 indica un governance risk più basso, mentre un punteggio di 10 indica un governance risk più alto.